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Abstract 
Medicinal plants used for the treatment of epilepsy are potentially a valuable source of novel 
anti-epileptic small molecules. To identify anticonvulsant secondary metabolites, we performed 
an in vivo, zebrafish-based screen of medicinal plants used in Southeast Asia for the treatment of 
seizures. Solanum torvum Sw. (Solanaceae) was identified as having significant anticonvulsant 
activity in zebrafish larvae with seizures induced by the GABAA antagonist pentylenetetrazol 
(PTZ). This finding correlates well with the ethnomedical use of this plant in the Philippines, 
where a water decoction of S. torvum leaves is used to treat epileptic seizures. HPLC 
microfractionation in 96-well plates of the bioactive crude extract, in combination with the in 
vivo zebrafish seizure assay, enabled the rapid localization of several bioactive compounds that 
were partially identified on-line by UHPLC-TOF-MS as steroid glycosides. Targeted isolation of 
the active constituents from the methanolic extract enabled the complete de novo structure 
identification of the six main bioactive compounds that were also present in the traditional 
preparation. In order to partially mimic the in vivo metabolism of these triterpene glycosides, 
their common aglycone was generated by acid hydrolysis. The isolated molecules exhibited 
significant anticonvulsant activity in zebrafish seizure assays. These results underscore the 
potential of zebrafish bioassay-guided microfractionation to rapidly identify novel bioactive 
small molecules of natural origin. 
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1. Introduction 
Epilepsy is a common neurological disorder characterized by the manifestation of spontaneous 
seizures as a result of abnormal neuronal activity in the brain. Currently known factors linked to 
the emergence of epilepsy are stroke, brain injury, brain tumors, infections such meningitis, but 
in 70% of cases the cause is not known (WHO, 2012). Epilepsy affects around 65 million people 
worldwide, especially children, and has a higher prevalence in tropical countries, particularly in 
Africa (Moshi et al., 2005; Thurman et al., 2011).  
Currently, there are a large number of antiepileptic drugs (AEDs), each of them being 
preferentially used depending on the type of seizure. Importantly, however, almost 30% of 
patients suffering from epilepsy remain resistant to these existing treatments (Perucca, 1998). 
Many currently available AEDs also exhibit serious neurological side effects such as depression, 
cognitive impairment, and sedation, in addition to other drug-induced toxicities such as 
gastrointestinal distress and hepatotoxicity (Arif et al., 2009; Arroyo and de la Morena, 2001; 
Carpay et al., 2005; Schmidt, 2009). For these different reasons there is a clear need to identify 
new AEDs with efficacy against pharmacoresistant epilepsy and ideally with minimal or no 
adverse effects. 
The identification of new AEDs is a significant challenge due to the heterogeneity and 
complexity of epileptic seizures. The evaluation of antiepileptic drug leads requires numerious in 
vitro and in vivo models which mimic the different mechanisms of action involved in epilepsy 
(Schmidt and Rogawski, 2002). In several in vivo assays, epilepsy is induced after administration 
of chemical proconvulsants such as the GABAA antagonist pentylenetetrazole (PTZ) in rodents 
(Galanopoulou et al., 2013), and in zebrafish (Danio rerio) (Baraban et al., 2005; Afrikanova et 
al., 2013). 
4 
 
In recent years, zebrafish have emerged as a novel experimental model for epilepsy (Baraban et 
al., 2005). Pentylenetetrazole (PTZ), a proconvulsant widely used to induce absence seizures and 
generalized tonic-clonic seizures in rodents, induces a dose-dependent series of stereotypical 
behaviors in 7 day-old zebrafish larvae, including clonus-type convulsions resembling epileptic 
seizures in mammals (Baraban et al., 2007). Epileptiform discharges were observed from 
electrophysiological recordings from the brains of PTZ-treated zebrafish larvae, with these 
discharges reduced by exposure to known anticonvulsant drugs such as valproate and diazepam. 
In order to facilitate the discovery of novel anti-epileptic drugs, an automated tracking system 
was developed to monitor the movement of zebrafish larvae in 96-well plates (Berghmans et al., 
2007; Orellana-Paucar et al., 2012; Afrikanova et al., 2013; Buenafe et al, 2013). Using this 
system, we found that similar anti-epileptic drugs were found to suppress PTZ-induced seizure-
like behaviors and electrographic activity in both zebrafish and mice, thereby validating the 
suitability of zebrafish for the high-throughput screening of potential anti-convulsant compounds 
(Afrikanova et al., 2013). 
The general paradigm of using zebrafish as a primary model organism for high-throughput 
screening in the context of natural-products drug discovery has been gaining ground in the past 
decade (Crawford et al, 2008, 2011). The advantages of zebrafish as a biological vertebrate 
model (e.g., fecundity, rapid ex utero development, ease of husbandry, genetic similarities to 
rodents and humans), when coupled with robust chromatographic and spectroscopic methods, 
have contributed to discoveries and further development of hit compounds from various plant 
extracts (Bohni et al., 2013; Buenafe et al., 2013; Orellana-Paucar et al., 2012). 
The sharpening focus on exploring plant extracts as sources for novel anticonvulsant drug 
candidates is not without compelling pretext, such as the historical use of medicinal plants to 
treat epilepsy (Sucher, 2006; Schachter, 2009), supported by anticonvulsant natural-product 
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molecules isolated from such plants to date (Orellana-Paucar et al, 2012 ; Buenafe et al, 2013). 
The impetus for such efforts can be attributed to the need to address drug-resistant epilepsy and 
to develop improved AEDs or even botanical therapeutics with reduced neurological and 
toxicological side effects (Schachter, 2009), especially since the potential of medicinal plants as 
source of chemical diversity for modern AED discovery cannot be disputed. 
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2. Results and discussion 
2.1 Zebrafish-based screen of Southeast Asian medicinal plant extracts 
Pre-screening was performed on nine Southeast Asian plants from the University of 
6WUDWKFO\GH¶V QDWXUDO product library (data not shown), which were selected on the basis of 
recorded ethnopharmacological use in Philippine pharmacopeia (Quisumbing, 1951). Solanum 
torvum was chosen for more rigorous assessment. Solanum torvum L. (Solanaceae) is a plant 
used in traditional medicine in South China and Southeast Asia as a sedative, digestive, 
hemostatic and diuretic (Zhu et al., 2003). In the Philippines this plant is traditionally used as an 
antiepileptic and antispasmodic (Quisumbing, 1951). The major constituents of this plant are 
steroidal saponins, which exhibit various bioactivities including anti-viral, cytotoxic, anti-
microbial, and anti-inflammatory (Colmenares et al., 2013; Lee et al., 2013; Lu et al., 2009; Shu 
et al., 2013). Anticonvulsant activity has previously been reported for solasodine, a steroidal 
alkaloid isolated from another Solanum species (S. Sisymbriifolium*) (Chauhan et al., 2011).  
Based on these findings, S. torvum was chosen for further bioactivity analysis, metabolite 
profiling, and bioassay-guided microfractionation to identify its anticonvulsant constituents. 
2.2 Bioactivity analysis of Solanum torvum 
The aerial parts of S. torvum were successively extracted with solvents of increasing polarity 
(hexane, dichloromethane, methanol and water) and concentrated under vacuum. The plant was 
also extracted by water infusion according to the traditional preparation. Zebrafish larvae (at 6.5-
dpf) were exposed to different concentrations of S. torvum crude extracts for 18 h before 
subsequent addition of PTZ, which induced seizure-like movement, such as swimming with 
LQFUHDVLQJDJLWDWLRQOHDGLQJWR³ZKLUOSRRO´EHKDYLRUORVVRISRVWXUHDQGFORQXs-type movement. 
The methanolic and water extracts that were likely to be close in composition to the traditional 
usage of the plant exhibited significant reduction (35-40%) of PTZ-induced movement in 6/7-dpf 
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larvae at 50 Pg/ml (p < 0.05), with their maximum tolerated concentrations (MTC) well beyond 
the highest tested concentration (200 µg/ml) (Figure 1A-D).  
2.3 Metabolite profiling  
The extracts were submitted to metabolite profiling by UHPLC-TOF-MS (Eugster et al., 2011) 
and their composition was compared (Figure 2). The methanol extract was selected for further 
chemical study, as it exhibited reduction in PTZ-induced activity in zebrafish larvae at a 
comparable level to the aqueous extract, and presents a wider array of metabolites. Based on the 
high resolution (HR)TOF-MS data obtained by metabolite profiling, the molecular formula of 
the compounds detected in the water infusion could be retrieved. These dereplication data 
revealed the presence of characteristic steroid glycosides isomers with a high molecular weight 
as the main LC peaks in the methanolic extract which were previously isolated from this plant 
(Colmenares et al., 2013; Lee et al., 2013; Lu et al., 2009; Shu et al., 2013). Because of the 
presence of many isomers known to have various absolute configurations or glycoside 
substitution patterns, a full structure assignment could not be performed based on such data 
alone. 
2.4 Bioactivity-guided microfractionation  
In order to rapidly localize the chromatographic zones of the HPLC chromatogram holding the  
anticonvulsant activity, reversed phase semi-preparative HPLC microfractionation of the crude 
methanolic extract (122 mg) was performed for metabolite profiling affording nine fractions (F1-
F9) (Figure 3A) (Wolfender and Queiroz, 2012). Each fraction has been submitted to the 
zebrafish anticonvulsant bioassay. Fraction 8 showed a significant reduction (35%) of PTZ-
induced movement at 50 Pg/mL (*) (Figure 3B). The UHPLC-TOF-MS analysis of this active 
microfraction showed mostly the presence of LC peaks having either a protonated molecules 
[M+H]+at m/z 741 or 727. This corresponded to isomeric compounds of molecular formula 
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C39H64O13 or C38H62O13. Such data matched well with previously isolated steroid glycosides 
from this plant (Colmenares et al., 2013; Lee et al., 2013; Lu et al., 2009; Shu et al., 2013). A 
differentiation of the various isomers present could however not be made based on MS data only. 
This rapid fractionation with only a few tenth of mg of crude extract however indicated that the 
steroid glycosides were responsible for the anticonvulsant activity of the extract measure in the 
in vivo assays. 
In order to fully characterize the active compounds and assess their activities quantitatively their 
isolation at a larger scale was needed. The separation was optimized by HPLC-UV-ELSD-MS. 
This procedure capitalizes on the HPLC modeling based on generic linear gradients at the 
analytical level to maximize the separation of interest compounds. These optimized analytical 
HPLC conditions were then transferred to medium pressure liquid chromatography (MPLC-UV-
ELSD) using the same C18 reverse stationary phase (Zeoprep®) and the same particle size (15-25 
Pm). Using this approach, 6 compounds were isolated in one step at the mg scale (Figure 4). 
2.5 Structural elucidation of the bioactive compounds 
Four compounds (1-4) displayed the same molecular formula (C39H64O13) assigned from their 
ESI-HRMS positive ion at m/z 741.4446 (eg for Torvoside J) (calcd. for C39H65O13 [M+H]+: 
741.4425). According to the Dictionary of Natural Products (The Chapman and Hall Dictionary 
of Natural Products on DVD, CRC Chemical Database), seven compounds, with the same 
spirostane skeleton, were found in the genus Solanum with this molecular formula. Namely, 
Torvoside C (this one was revised to Torvoside K by Iida et al., 2005), Torvoside J-L, 
Paniculonin B, Spirotorvoside and Melongoside E. The 1H NMR spectra of 1-4 showed a very 
similar pattern in agreement with glycosylated spirostane: two methyl singlets (Me-18 and Me-
19), four methyl doublets, two belonging to the spirostane (Me-21 and Me-27) and two to the 
sugars moieties (Me-6' and Me-6'') and two anomeric doublets at GH 5.14 (J = 1.7 Hz, H-1') and 
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4.27 (J = 7.9 Hz, H-1''). The COSY, TOCSY and HSQC spectra allowed identifying the sugars 
as a quinovose and a rhamnose. The long range HMBC correlations from H-3' of the quinovose 
(GH 3.42, t, J= 8.9 Hz) to C-1'' of the rhamnose (GC 102.8) and from H-1' of the quinovose to C-6 
of the spirostane (GC 80.4) indicated that the four compounds belong to the following type: 
3E,6D,23-trihydroxy-5D-spirostane 6-O-E-D-rhamnopyranosyl-ĺ-O-E-D-quinovopyranosyl. 
Melongoside E and Spirotorvoside being spirostane 3-O-glycoside they were thus excluded from 
the list of possible structures. At this stage, Torvoside J, K, L and Paniculonon B remain the four 
possible structures which differ only from their configuration at C-22, C-23 and C-25. According 
to Y. Iida et al. (Chem. Pharm. Bull. 2005) the GC at C-20 and GH at Me-21 (in pyridine-d5) are 
diagnostic for the determination of the configuration at C-22: GH 1.07-1.26 and GC 35.0-36.2 for 
22-D-O-spirostanol (22-S) and GH 1.53-1.54 and GC43.1-44.1 for 22-E-O-spirostanol (22-R). As 
the NMR data have been recorded in CD3OD (the solvent used for the dereplication database) a 
direct comparison with the reported data was not possible. However, compounds 1, 2, 3 and 4 
could be split into two groups based on their chemical shift values at C-20 and Me-21. The 13C 
chemical shifts recorded in CD3OD being very close to those obtained in pyridine-d5, we 
concluded that 1, 2 and 3 were 22-R with the following GH(Me-21)/GC(C-20): 1.10/41.6, 
1.12/40.8 and 1.16/43.6 whereas 4 exhibited a 22-S configuration (GH(Me-21)/GC(C-20): 
0.96/37.0). The configuration of C-23 could be deduced from the H-23 coupling constant (dd (J 
= 10.3/5.2 Hz) when H-23 was in axial position and a triplet (J = 3Hz) when H-23 was in 
equatorial position). The configuration at C-25 was usually determined by the signal pattern of 
H-26 (brd (J = 11.0 Hz) and dd, (J = 11.0, 3.0 Hz) when H-25 is equatorial and t (J = 11.0 Hz) 
and brd, (J = 11.0Hz) when H-25 is axial). The GH of Me-27 was also characteristic as it appear 
shifted downfield in axial position (1.10-1.16) compared to the equatorial position (0.77-0.82). 
Based on these observations, compound 1 was unambiguously identified as Torvoside J (22R, 
23S, 25S), 2 as Torvoside L (22R, 23R, 25S), 3 as Torvoside K (22R, 23S, 25R) (Y. Iida et al. 
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Chem. Phar. Bull. 2005) and 4 to Paniculonin B (22S, 23S, 25S) (C-L. Lee et al. Phytochem 
1995). 
The other isolated compounds (5 and 6) shared a same molecular [M+H]+ ion at (eg m/z 
727.4302 for Paniculonin A) (calcd. for C38H63O13 [M+H]+: 727.4269) indicating a molecular 
formulae of C38H62O13 shifted by 14 Da compare to 1-4. The 1H NMR spectrum of 5 was very 
close to that of Torvoside J (1) at the exception of the sugar region. The missing methyl doublet 
at GH 1.25 (CH3-6'') in 1 and the lack of CH2 in the molecular formulae suggested the presence of 
a pentose instead of a hexose. The second sugar was identified as a xylose (GH/GC 4.48/106.0 for 
H/C-1'', 3.26/75.3 for H/C-2'', 3.33/77.7-3 for H/C-3'', 3.49/71.0 for H/C-4'' and 3.23,3.90/67.1 
for H/C-5''). Compound 5 was thus (22R,23S,25S)-3E,6D,23-trihydroxy-5D-spirostane 6-O-E-D-
xylopyranosyl-ĺ-O-E-D-quinovopyranoside (Lu et al. Phytochem 2011). The 1H NMR of 6 
displayed the same sugar pattern as 5 and the same spirostane pattern as Paniculonin B (4). 
Compound 6 was elucidated as Paniculonin A (M. Gonzalez et al. J. Nat. Prod. 2004). The NMR 
description of all these compounds have not yet been reported in CD3OD, which is a common 
solvent used for at-line dereplication by micro-NMR methods, and they are thus detailed in the 
experimental section. 
2.6 Acid hydrolysis of the glycosides 
Triterpene glycosides are known to have poor intestinal absorption mainly due to their 
unfavorable physicochemical properties, such as large molecular mass (>500 Da), high 
hydrogen-bonding capacity (>12), and high molecular flexibility (>10), that underlie poor 
membrane permeability (Yu et al., 2012). Assuming that the isolated steroid glycosides from S. 
torvum may be pro-drugs, the fraction containing the triterpene glycosides was submitted to a 
mild acid hydrolysis (refluxed with 2% H2SO4/MeOH for 8 days at 37°C) to provide the 
corresponding aglycones (Kesselmeier and Budzikiewicz, 1979) that could mimic an initial 
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degradation step in the stomach (Yu et al., 2012). The hydrolysis afforded mainly one compound 
(C22H34O4) ([M+H]+ at m/z 363.2543 (calculated for C22H34O4, 363.2535, 2.2 ǻppm)). The NMR 
analysis of the HSQC spectrum of the hydrolyzed product revealed the absence of sugar signals 
as well as the characteristic signals belonging to the spirostane ring (eg. the oxymethine CH-23 
and oxymethylene CH2-26). Moreover, a careful analysis of signals indicated that the hydrolyzed 
product consist of a 65/35 mixture of two aglycones as seen by the duplication of signals for H-
16 (GH/GC 5.03/84.6 and 4.83/84.1), H-20 (GH/GC 2.60/37.4 and 2.97/38.7), H-17 (GH/GC 1.98/59.9 
and 22.31/56.6), Me-21 (GH/GC 1.28/17.9 and 1.30/10.3) and Me-18 (GH/GC 0.73/13.9 and 
0.81/14.0). Despite these differences in chemical shifts, the HMBC correlations were the same in 
both molecules: from Me-21 to C-17, C-20 and the ester carbonyl at GC 183.9/182.2 and from 
Me-18 to C1-2, C-13, C-14 and C-17. The two aglycones were thus epimers. Analysis of the 
NOESY correlations indicated that the first one was solanolide (A.K. Chakravarty et al. 
Phytochemistry, 1982) as seen by the dipolar correlation from H-16 to Me-21 and H-17 and from 
H-20 and Me-18. For the second isomer, the NOE crosspeaks from H-16 to H-17 and H-20 and 
from Me-21 to Me-18 showed that it was the epimer of solanolide at C-20. The mechanism for 
production of these aglycones (7a and 7b) was already speculated for the study of similar 
compounds in Solanum anguivi (Nafady et al., 2003).  
2.7 Bioactivity analysis of isolated compounds in vivo 
The six isolated S. torvum steroidal glycosides and the aglycone from acid-hydrolysis 
(compounds 1-7) were subjected to further biological activity analyses. The selected compounds 
were exposed to 6/7-dpf zebrafish larvae for 18 h in various concentrations, with their MTC 
values beyond the highest concentration (280 µM, with the exception of compound 1, which was 
at 140 µM), before subsequent exposure to 20 mM PTZ (Figure 5). Compounds 4 - 6 did not 
show significant reduction in PTZ-induced locomotor activity in larvae (Figure 5-4, 5-5, 5-6). 
Inconsistent reduction of PTZ-induced activity over the 30-minute exposure time was seen for 
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compounds 2 and 3 (Figure 5-2, 5-3), although they display reduction of total movement only at 
70 µM (Figure 5-7). Compound 1 showed significant reduction of PTZ-induced activity from 70 
µM (moderate, P < 0.05) until 140 µM (P < 0.001) (Figure 5-1). As these compounds have 
similar structures, the slight difference in compound 1 (the stereochemical positions of ±OH and 
±CH3 in the spirostane ring) compared to the other identified torvosides (2,3) may play a role in 
activity modulation, as well as the type of sugar moiety attached to the aglycone (5) (Figure 4). 
However, significant reduction of PTZ-induced activity in larvae was also observed for acid-
hydrolysis aglycone 7 at its MTC value (140 µM) (Figure 6A), indicating that the presence of a 
sugar moiety may not be necessary.  
The structures of the steroidal glycosides isolated from S. torvum, especially their acid-
hydrolysis aglycone product, bear resemblance to neurosteroids (e.g., alphaxalone, 
pregnanolone, allopregnanolone, ganaxolone) which are known to interact with GABA 
receptors, and have been used as anesthetics and sedatives (Child et al, 1971; Lan, 1994). One 
such neurosteroid, ganaxolone, a potent GABAA modulator, shows anticonvulsant properties 
(Carter et al., 1997) and is now facing Phase III clinical trials (Bialer et al, 2013) on adult 
patients suffering from partial seizures. Based on the similarity of structure to the isolated 
compounds and its known pharmacology and mode of action, ganaxolone was selected as a 
reference drug for comparison purposes in larval zebrafish PTZ assays. Upon exposure to larval 
zebrafish prior to addition of PTZ, ganaxolone (8) has shown to significantly reduce the 
influence of PTZ on the locomotor activity of 7-dpf zebrafish larvae at 0.3 nM (Figure 6B). 
Comparing the reduction of PTZ-induced activity of ganaxolone with any of the isolated S. 
torvum compounds (and aglycone), we observed that there is a large difference in the order of 
magnitude in terms of potencies of the compounds. 
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2.8 Bioactivity analysis of isolated compounds in vitro 
Since neurosteroids are known to be GABAA modulators and the aglycone (7) present a related 
steroid structural type, we used Xenopus laevis oocyte expression system to test the effects of 
different compounds on the activity of GABAA UHFHSWRUVFRPSULVLQJĮȕ DQGȖV VXEXQLWV 
(Abdullah and Zhang, 2013). To check the expression level a test pulse with 1mM GABA was 
applied at the beginning of each recording. After thorough washing 10 µM ganaxolone, 
pregnanolone, S. torvum crude extract or compound 7 were applied and the obtained response 
normalized to the test pulse. Pregnanolone, the crude extract and the aglycone (7) produced 
smaller currents compared to the currents generated by ganaxolone (8). All novel compounds 
elicited currents resembling the ones induced by GABA (Figure 7A, B). 
In a different set of experiments we examined the potentiation effect on GABAA receptor 
response known for pregnanolone and allopregnanolone (Reddy, 2010). Here the first application 
of 10 µM GABA was followed by application of 10µM GABA mixed with 10µM or 100µM of 
each tested compound. Washing times in between applications was 5 minutes and all responses 
were normalized to the current produced by 10 µM GABA in the same cell. Except for 
application of 10 µM GABA together 100 µM pregnanolone, all other currents were 2-3 fold 
reduced compared to the ones generated by 10 µM GABA. These results indicate that the 
isolated compounds from S. torvum are weak modulators of GABA receptors compared to 
ganaxolone or pregnanolone. 
The disparate order of magnitude of difference in potencies (sub-nanomolar vs micromolar) 
between ganaxolone and the S. torvum aglycone (or even the parent steroidal glycosides) in the 
larval zebrafish assay may be accounted for the structural differences between them. The 
fundamental criterion for a neurosteroid to be effective in modulating GABA receptors is that the 
compound should possess a hydrogen bond donor at C- LQ WKH VWHURLG VNHOHWRQ Į-OH), 
coupled with a hydrogen bond acceptor at C-RQ WKHȕSODQHRI WKH VNHOHWRQ &RYH\
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Akk, 2007). Beside being of the same structural type as ganaxolone, the acid-hydrolyzed 
aglycone (7) exhibited several main differences such as ȕ-OH instead of the alpha 
configuration, a furan-type ring fused at C16-C17 instead of a COCH3 at C.17 and altogether this 
may explain a different mode of action for both molecules. 
The results obtained indicate, based on the hypothesis of a possible link between the mode of 
actions of ganoxolone and the steroids of S. torvum, that the isolated compounds are not equally 
as potent as ganaxolone as GABAA modulators, as reflected by the larval zebrafish results as 
well as from the X. laevis oocyte receptor overexpression system. It can thus be hypothesize that 
the reduction of PTZ-induced activity of S. torvum extract and compounds may be due to 
mechanisms other than the GABA inhibitory system. 
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3. Conclusion 
This work presents a new strategy of combining HPLC micro-fractionation with at-line  
bioactivity assessment on an in vivo zebrafish behavioral epilepsy assay. It has allowed an 
efficient localization of bioactive steroid glycoside and served for an efficient targeted isolation 
of the bioactive compounds. 
The isolation procedure was performed by direct geometrical gradient transfer from analytical 
HPLC-ELSD to preparative medium pressure liquid chromatography (MPLC-ELSD) and 
allowed an efficient isolation of the active compounds at large amount. The bioguided isolation 
afforded six spirostane glycosylated triterpenes that were responsible for the antiepileptic activity 
of the infusion and methanolic extract of aerial parts of Solanum torvum. These compounds 
presented anticonvulsant activity in the in vivo zebrafish model but no specificity was recorded 
among the different glycoside tested. Since the presumed bioavailability of such compounds is 
poor and they might undergo hydrolysis when taken orally, as it the case with the traditional 
preparation, we demonstrated that these compounds could generate an active aglycone through a 
skeleton rearrangement under mild hydrolysis conditions. Despite the structural resemblance to 
neurosteroids such as ganaxolone, these isolated steroidal glycosides and aglycone offer only 
weak GABA modulation, thus indicating that these compounds may act on a different 
mechanism of action to significantly reduce PTZ-induced seizure activity in zebrafish. 
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4. Materials and methods 
General Experimental Procedures. NMR spectroscopic data were recorded on a 500 MHz 
Agilent/Varian Inova spectrometer. Chemical shifts are reported in parts per million (į) using the 
residual CD3OD signal (įH 3.31; įC 49.0) as internal standards for 1H and 13C NMR, and 
coupling constants (J) are reported in Hz. Complete assignment was performed based on 2D 
experiments (COSY, TOCSY, NOESY, edited-HSQC and HMBC). ESI-HRMS data were 
obtained on a Micromass LCT Premier time-of-flight mass spectrometer from Waters with an 
electrospray ionization (ESI) interface (Waters, Milford, MA, USA). Analytical HPLC was 
performed using an HP 1100 system equipped with a photodiode array detector (Agilent 
Technologies, Santa Clara, CA, USA). MPLC was performed using a Büchi 681 pump (Büchi, 
Flawil, Switzerland) equipped with a Knauer UV detector (Knauer, Berlin, Germany) and a 920 
x 49 mm i.d. column (Büchi, Flawil, Switzerland) loaded with ZEOprep® C18 as the stationary 
phase 15-25 Pm (Zeochem, Uetikon am See, Switzerland).  
Plant material. The aerial parts of Solanum torvum was collected in Infanta, Quezon in the 
Philippines in 2011. The botanical material was properly identified, with voucher specimen 
#2796, deposited in the Herbarium of the Institute of Biology of the University of the Philippines 
(UP Diliman). A Material Transfer Agreement for the collection and transfer of S. torvum 
material from the Philippines to Belgium, in concordance with the UN Convention on 
Biodiversity, has been signed between KU Leuven and Ateneo de Manila University. 
Preparation of extract. The dried aerial parts (102.24 g) were successively extracted under 
maceration and agitation with increasing polarity extraction in a round-bottom flask using a 
sequence of solvents of increasing polarity (hexane, dichloromethane, methanol and water) and 
concentrated under vacuum to yield 2.15 g of hexane (2.1%), 1.73 g (1.7%) of dichloromethane, 
and 13.59 g of methanol (13.3%). The aqueous extract was frozen and lyophilized yielding 1.83 
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g (1.8%) of water extract. Traditional decoction has been prepared using 10 g of dried aerial part 
of S. torvum in 100 ml of hot water during 1 hour a comparison of the profile with simple 
infusion for example revealed the presence of similar compounds. The solution is filtrate and 
evaporated to dryness yield 1.6 g (16%).  
HPLC-DAD-ELSD-MS Analysis.HPLC-DAD-ELSD-MS data were obtained with an Agilent 
HP 1100 series system consisting of an autosampler, high-pressure mixing pump and DAD 
detector (Agilent Technologies, Santa Clara, CA, USA) connected to a Finnigan MAT LCQ ion 
trap mass spectrometer (Finnigan, San Jose, CA, USA) equipped with a Finnigan electrospray 
interface (ESI) and a ELSD detector Sedex 85 (Sedere, Oliver, France). The HPLC conditions 
were as follows: an Zeoprep® C-18 column (15-25 µm, 250 x 4.6 mm i.d. (this particle size was 
selected for an optimum gradient transfert the MPLC) (Zeochem, Uetikon am See, Switzerland); 
solvent system: A, H2O  containing 0.1% formic acid and B, ACN containing 0.1% formic acid; 
step gradient: 2 to 27% of B in 5 min followed by 27% of B for 20 min, then 27% B to 36% of B 
in 5 min, followed by 36% B for 20 min and 36% to 95% of B in 10 min; flow rate: 1 ml min-1; 
injection volume: 10 µl; and sample concentration: 10 mg/ml in MeOH. The samples are 
analysed with UV detection and the absorbance was measured at 280 nm and ELSD detection. 
ESI-MS conditions were as follows: capillary voltage: 30 V; capillary temperature: 200 °C; 
source voltage: 4.5 kV; source current: 80 µA; nitrogen as the sheath gas; and positive and 
negative ion mode. Spectra (180-1200 mu) were recorded every 3 s. 
UHPLC-TOF-HRMS analyses. HRMS metabolite fingerprint of the extracts was performed on 
a Micromass-LCT Premier Time of Flight (TOF) mass spectrometer (Waters, Milford MA, 
USA) equipped with an electrospray interface and coupled to an Acquity UPLC system (Waters, 
Milford MA, USA). The ESI conditions were as follows: capillary voltage 2800 V, cone voltage 
40 V, MCP detector voltage 2400 V, source temperature 120°C, desolvation temperature 300°C, 
cone gas flow 20 L/h, and desolvation gas flow 600 L/h. Detection was performed in positive ion 
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mode (PI) with a m/z range of 100±1300 Da and a scan time of 0.5 s in the W-mode. The MS 
was calibrated using sodium formate, and leucine encephalin (Sigma-Aldrich, Steinheim, 
*HUPDQ\ ZDV XVHG DV DQ LQWHUQDO UHIHUHQFH DW  ȝJP/ DQG LQIXVHG WKURXJK D /RFN 6SUD\
SUREHDWDIORZUDWHRIȝ/PLQZLWKWKHKHOSRIDVHFRQG/&SXPS 
The general profiling of the extract was performed on a Acquity BEH C18 UPLC column (150 
×2.1 mm i.d.; 1.7 µm, Waters, Milford, MA, USA) using a linear gradient from 5% ACN+0.1% 
FA to 95% of B in 30 min, while for the separation of the isomers the following otpimised 
conditions were used:Acquity BEH C18 UPLC column (50 ×2.1 mm i.d.; 1.7 µm, Waters, 
Milford, MA, USA) using a stepgradient (solvent system: A= 0.1% formic acid±water, B= 0.1% 
formic acid±acetonitrile; gradient: 5±36% B in 1 min, then 36% B to 36% B in 2 min, 36% B to 
95% B in 1.5 min; flow rate 1.1 ml/min). The temperature was set to 40°C. The injected volume 
was kept constant (1 µL). 
Semi preparative HPLC-UV microfractionation. A first fractionation allowed the localisation 
of the active area on the chromatogram. The fractionation was performed on a5 µm Xterra prep 
Column C18 OBD (150x19mm, 5 µm). The gradient start with 100% of mobile phase A 
(H2O+0.1% FA) to 60% of mobile phase B (ACN +0.1% FA) in 56 min.13 Fractions were 
collected every 3 minutes were the separation couls be monitored by UV. Fraction 1 has been 
obtained by pooling 3 successives fractions, F4 and F5 by pooling 2 successives fractions. The 
non UV active part was pooled into two main fractions (F8 and F9). 
Isolation of active compounds from the methanolic extract. The methanolic extract (4 g) was 
first fractionated using MPLC with Zeoprep® C18 as the stationary phase (15-25 µm, 920 x 49 
mm i.d.) (Zeochem, Uetikon am See, Switzerland) ACN and H2O containing 0.1% formic acid 
as mobile phase in a step gradient as the following: 2-27% B for 9.5 hours, isocratic 27% B for 
31.5 hours, 27-36% B for 8 hours, isocratic 36% for 32 hours, 36-95% B for 16 hours, isocratic 
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95% B for 16 hours for 113 hours as a total of purification time. The flow rate was 4 ml min-1, 
and the UV absorbance was detected at 280 nm. The ELSD detection was performed under the 
following parameters: pressure 3.2 bars, 45°C, split to provide a 500 µl/min Flow rate, gain 8. 
The MPLC yielded 182 fractions. All fractions were analysed by UHPLC-TOF-MS. Fraction 71 
yielded compound 1, Torvoside J (9.4 mg), fraction 80 yielded 2, F80 (3.4 mg), fraction 88A 
yielded 3, Torvoside K (7 mg), fraction 88B  yielded 4, Torvoside L (7 mg), fraction 117 yielded 
5 Paniculin B (2.2 mg), and fraction 128 yielded 6, Paniculin A (1.6 mg) all the other fractions 
were selected for further purification. 
Hydrolysis conditions for obtaining the aglycone 7. In order to obtain the aglycone from the 
spirostane glycoside, a mild hydrolysis has been performed. Indeed, classical acidic hydrolysis 
induces a destruction of the spirostane. The mild hydrolysis protocol was based on the one 
described by Kesselmeier et al., in 1979 except the HCl has been replaced by H2SO4. Aglycone 
was obtained by subjecting glycoside of interest to a solution 2% H2SO4 in MeOH at 37°C 
during 8 days.  
Spectral data of the isolated compounds 
Compound 1, Torvoside J. H NMR (CD3OD, 500 MHz) G 0.68 (1H, td, J=11.3, 3.6 Hz, H-9), 
0.77 (3H, d, J=6.6 Hz, Me-27), 0.81 (3H, s, Me-18), 0.87 (3H, s, Me-19), 0.95 (1H, m, H-7b), 
1.02 (1H, m, H-1b), 1.10 (3H, d, J=6.9 Hz, Me-21), 1.13 (1H, m, H-12b), 1.15 (2H, m, H-4b, H-
5), 1.16 (1H, m, H-14), 1.25 (3H, d, J=6.2 Hz, Me-6''), 1.27 (1H, m, H-15b), 1.28 (3H, d, J=6.2 
Hz, Me-6'), 1.32 (1H, m, H-11b), 1.41 (1H, m, H-2b), 1.54 (1H, m, H-11a), 1.61 (1H, m, H-24b), 
1.64 (1H, m, H-8), 1.66 (1H, m, H-24a), 1.69 (1H, m, H-17), 1.70 (1H, m, H-1a), 1.74 (1H, m, 
H-12a), 1.75 (1H, m, H-2a), 1.98 (1H, m, H-15a), 2.04 (1H, m, H-25), 2.17 (1H, dt, J=12.5, 4.1 
Hz, H-7a), 2.25 (1H, p, J=6.9 Hz, H-20), 2.38 (1H, m, H-4a), 3.02 (1H, t, J=8.9 Hz, H-4'), 3.28 
(1H, dd, J=8.9, 7.9 Hz, H-2'), 3.31 (1H, m, H-5'), 3.36 (1H, m, H-26b), 3.38 (1H, m, H-6), 3.40 
(1H, t, J=9.6 Hz, H-4''), 3.43 (1H, t, J=8.9 Hz, H-3'), 3.46 (2H, m, H-3, H-26a), 3.53 (1H, t, 
J=3.0 Hz, H-23), 3.70 (1H, dd, J=9.6, 3.3 Hz, H-3''), 3.94 (1H, brs, H-2''), 3.99 (1H, dq, J=9.6, 
6.2 Hz, H-5''), 4.27 (1H, d, J=7.9 Hz, H-1'), 4.46 (1H, q, J=6.9 Hz, H-16), 5.14 (1H, brs, H-
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1'')13C NMR (CD3OD, 126 MHz) G 13.9 (C-19), 16.8 (C-18), 17.1 (C-21), 17.4 (C-27), 17.9 (C-
6''), 18.4 (C-6'), 22.0 (C-11), 24.9 (C-25), 31.8 (C-2), 32.7 (C-4), 32.9 (C-15), 35.2 (C-8), 37.5 
(C-10), 37.6 (C-24), 38.4 (C-1), 40.7 (C-12), 41.6 (C-7, C-20), 42.0 (C-13), 51.7 (C-5), 55.0 (C-
9), 57.4 (C-14), 65.6 (C-17), 67.5 (C-26), 70.0 (C-5''), 71.0 (C-23), 71.8 (C-3), 72.2 (C-3''), 72.3 
(C-2''), 72.9 (C-5'), 73.9 (C-4''), 75.7 (C-4'), 76.3 (C-2'), 80.3 (C-6), 82.3 (C-16), 84.2 (C-3'), 
102.7 (C-1''), 105.1 (C-1'), 109.9 (C-22). ESI-HRMS m/z 741.4437 [M+H]+ (calculated for 
C39H65O13, 741.4425, ǻppm = 1.6) 
 
Compound 2, Torvoside L. 1H NMR (CD3OD, 500 MHz) G 0.69 (1H, m, H-9), 0.82 (3H, d, 
J=6.4 Hz, Me-27), 0.87 (3H, s, Me-18), 0.88 (3H, s, Me-19), 0.94 (1H, q, J=12.2Hz, H-7b), 1.02 
(1H, brt, J=12.7 Hz, H-1b), 1.12 (1H, m, H-14), 1.14 (1H, m, H-4b), 1.16 (2H, m, H-5, H-12b), 
1.16 (3H, d, J=7.2 Hz, Me-21), 1.24 (3H, d, J=6.2 Hz, Me-6''), 1.28 (1H, m, H-15b), 1.28 (3H, d, 
J=6.2 Hz, Me-6'), 1.35 (1H, m, H-11b), 1.41 (1H, m, H-2b), 1.48 (1H, q, J=11.8Hz, H-24b), 1.55 
(1H, d, J=13.7 Hz, H-11a), 1.66 (1H, m, H-8), 1.71 (1H, m, H-1a), 1.74 (1H, m, H-12a), 1.75 
(2H, m, H-2a, H-25), 1.79 (1H, m, H-24a), 1.84 (1H, dd, J=9.1, 6.3 Hz, H-17), 1.96 (1H, dq, 
J=12.1, 6.5Hz, H-15a), 2.17 (1H, m, H-7a), 2.20 (1H, m, H-20), 2.38 (1H, m, H-4a), 3.02 (1H, t, 
J=9.1Hz, H-4'), 3.26 (1H, dd, J=9.3, 8.0 Hz, H-2'), 3.30, (1H, m, H-26b), 3.31 (1H, m, H-5'), 
3.39 (2H, m, H-6, H-4''), 3.42 (1H, m, H-3'), 3.43 (1H, m, H-26a), 3.45 (1H, m, H-3), 3.63 (1H, 
dd, J=11.5, 4.6 Hz, H-23), 3.69 (1H, dd, J=9.5, 3.4 Hz, H-3''), 3.93 (1H, dd, J=3.4, 1.8 Hz, H-
2''), 3.99 (1H, m, H-5''), 4.27 (1H, d, J=8.0 Hz, H-1'), 4.71 (1H, q, J=7.6 Hz, H-16), 5.14 (1H, d, 
J=1.8 Hz, H-1'')13C NMR (CD3OD, 126 MHz) G 13.6 (C-19), 16.2 (C-21), 16.6 (C-27), 17.0 (C-
18), 17.7 (C-6''), 18.2 (C-6'), 21.8 (C-11), 31.6 (C-25), 31.8 (C-2), 32.5 (C-4), 34.5 (C-15), 34.9 
(C-8), 38.2 (C-1), 38.3 (C-24), 41.0 (C-12), 41.5 (C-7),43.6(C-20), 51.6 (C-5), 54.9 (C-9), 56.5 
(C-14), 64.1 (C-17), 69.3 (C-26), 69.9 (C-5''), 70.6 (C-23), 71.7 (C-3), 72.1 (C-3''), 72.2 (C-2''), 
72.8 (C-5'), 73.9 (C-4''), 75.5 (C-4'), 76.2 (C-2'), 80.2 (C-6), 84.2 (C-3'), 85.2 (C-16), 102.6 (C-
1''), 104.9 (C-1'). ESI-HRMS m/z 741.4446 [M+H]+ (calculated for C39H65O13, 741.4425, 
ǻSSP 2.8). 
 
Compound 3, Torvoside K. 1H NMR (CD3OD, 500 MHz) G 0.69 (1H, m, H-9), 0.82 (3H, s, 
Me-18), 0.87 (3H, s, Me-19), 0.95 (1H, m, H-7b), 1.02 (1H, m, H-1b), 1.12 (3H, d, J=7.0 Hz, 
Me-21), 1.14 (2H, m, H-4b, H-12b), 1.16 (1H, m, H-5), 1.17 (1H, m, H-14), 1.21 (3H, d, J=7.3 
Hz, Me-27), 1.24 (3H, d, J=6.2 Hz, Me-6''), 1.27 (1H, m, H-15b), 1.28 (3H, d, J=6.1 Hz, Me-6'), 
1.32 (1H, m, H-11b), 1.40 (1H, m, H-2b), 1.52 (1H, m, H-24b), 1.55 (1H, m, H-11a), 1.65 (1H, 
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m , H-8), 1.67 (1H, m, H-25), 1.70 (1H, m, H-17), 1.71 (1H, m, H-1a), 1.75 (2H, m, H-2a, H-
12a), 1.96 (1H, m, H-15a), 2.06 (1H, m, H-24a), 2.17 (1H, m, H-7a), 2.35 (1H, m, H-20), 2.38 
(1H, m, H-4a), 3.01 (1H, t, J=9.0 Hz, H-4'), 3.26 (1H, dd, J=9.0, 7.9 Hz, H-2'), 3.31 (2H, m, H-
26b, H-5'), 3.39 (2H, m, H-6, H-4''), 3.42 (1H, t, J=9.0 Hz, H-3'), 3.45 (1H, m, H-3), 3.57 (1H, t, 
J=3.9 Hz, H-23), 3.69 (1H, dd, J=9.5, 3.4 Hz, H-3''), 3.93 (1H, dd, J=3.4, 1.7 Hz, H-2''), 3.96 
(1H, dd, J=11.2, 3.8 Hz, H-26a), 3.99 (1H, dq, J=9.5, 6.2 Hz, H-5''), 4.27 (1H, d, J=7.9 Hz, H-
1'), 4.47 (1H, q, J=7.8 Hz, H-16), 5.14 (1H, d, J=1.7 Hz, H-1'')13C NMR (CD3OD, 126 MHz) G 
13.6 (C-19), 16.6 (C-18), 16.7 (C-21), 17.7 (C-6''), 18.1 (C-6'), 20.0 (C-27), 21.9 (C-11), 27.7 
(C-25), 31.6 (C-2), 32.4 (C-4), 32.7 (C-15), 34.3 (C-24), 35.0 (C-8), 38.3 (C-1), 40.7 (C-12), 
40.8 (C-20), 41.5 (C-7), 51.6 (C-5), 54.9 (C-9), 57.3 (C-14), 65.2 (C-17), 66.0 (C-26), 69.8 (C-
5''), 71.0 (C-23), 71.6 (C-3), 72.0 (C-3''), 72.2 (C-2''), 72.8 (C-5'), 73.9 (C-4''), 75.5 (C-4'), 76.2 
(C-2'), 80.2 (C-6), 82.4 (C-16), 84.0 (C-3'), 102.7 (C-1''), 105.0 (C-1'). ESI-HRMS m/z 741.4453 
>0+@FDOFXODWHGIRU&+2ǻSSP 3.8).  
 
Compound 4, Paniculonin B. 1H NMR (CD3OD, 500 MHz) G 0.69 (1H, td, J=12.0, 3.9 Hz, H-
9), 0.86 (3H, s, Me-18), 0.88 (3H, s, Me-19), 0.95 (1H, m, H-7b), 0.96 (3H, d, J=7.0 Hz, Me-21), 
1.03 (1H, m, H-1b), 1.11 (3H, d, J=6.8 Hz, Me-27), 1.14 (1H, m, H-4b), 1.16 (1H, m, H-5), 1.17 
(1H, m, H-12b), 1.18 (1H, m, H-14), 1.24 (3H, d, J=6.2 Hz, Me-6''), 1.27 (3H, d, J=6.1 Hz, Me-
6'), 1.33 (1H, m, H-11b), 1.41 (2H, m, H-2b, H-15b), 1.55 (1H, brd, J=13.6 Hz, H-11a), 1.67 
(2H, m, H-8, H-24b), 1.71 (1H, m, H-1a), 1.75 (2H, m, H-2a, H-12a), 1.76 (1H, m, H-17), 1.89 
(1H, m, H-25), 1.90 (1H, m, H-24a), 1.96 (1H, m, H-15a), 2.18 (1H, dt, J=12.5, 4.0 Hz, H-7a), 
2.38 (1H, m, H-4a), 2.53 (1H, p, J=7.0 Hz, H-20), 3.01 (1H, t, J=9.0 Hz, H-4'), 3.19 (1H, d, 
J=11.0 Hz, H-26b), 3.26 (1H, dd, J=9.0, 7.9 Hz, H-2'), 3.31 (1H, m, H-5'), 3.39 (1H, t, J=9.5 Hz, 
H-4''), 3.39 (1H, m, H-6), 3.42 (1H, t, J=9.0 Hz, H-3'), 3.45 (1H, m, H-3), 3.67 (1H, dd, J=11.3, 
5.0 Hz, H-23), 3.69 (1H, dd, J=9.5, 3.3 Hz, H-3''), 3.85 (1H, dd, J=11.0, 2.4 Hz, H-26a), 3.93 
(1H, dd, J=3.3, 1.8 Hz, H-2''), 3.99 (1H, dq, J=9.5, 6.2 Hz, H-5''), 4.27 (1H, d, J=7.9 Hz, H-1'), 
4.44 (1H, q, J=7.5 Hz, H-16), 5.14 (1H, d, J=1.8 Hz, H-1''). 13C NMR (CD3OD, 126 MHz) į 
13.8 (C-19), 14.3 (C-21), 17.0 (C-18), 17.6 (C-27), 17.9 (C-6''), 18.4 (C-6'), 22.1 (C-11), 31.3 
(C-25), 31.9 (C-2), 32.6 (C-15), 32.7 (C-4), 35.1 (C-8), 36.0 (C-24), 37.0 (C-20), 37.6 (C-10), 
38.5 (C-1), 41.3 (C-12), 41.7 (C-7), 42.2 (C-13), 51.8 (C-5), 55.1 (C-9), 57.4 (C-14), 63.2 (C-
17), 64.0 (C-23), 65.0 (C-26), 70.0 (C-5''), 71.9 (C-3), 72.3 (C-3''), 72.4 (C-2''), 73.0 (C-5'), 74.0 
(C-4''), 75.7 (C-4'), 76.4 (C-2'), 80.4 (C-6), 82.6 (C-16), 84.3 (C-3'), 102.8 (C-1''), 105.1 (C-1'), 
112.6 (C-22). ESI-HRMS m/z 741.4438 [M+H]+ FDOFXODWHGIRU&+2ǻSSP 
1.8). 
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Compound 5, (22R,23S,25S)-3E,6D,23-trihydroxy-5D-spirostane6-O-E-D-xylopyranosyl-
ĺ-O-E-D-quinovopyranoside.1H NMR (CD3OD, 500 MHz) G 0.69 (1H, td, J=11.5, 4.2 Hz, 
H-9), 0.77 (3H, d, J=6.6 Hz, Me-27), 0.81 (3H, s, Me-18), 0.87 (3H, s, Me-19), 0.97 (1H, m, H-
7b), 1.03 (1H, m, H-1b), 1.09 (3H, d, J=7.0 Hz, Me-21), 1.14 (2H, m, H-4b, H-12b), 1.16 (1H, 
m, H-5), 1.18 (1H, m, H-14), 1.27 (3H, d, J=6.0 Hz, Me-6'), 1.27 (1H, m, H-15b), 1.32 (1H, m, 
H-11b), 1.41 (1H, m, H-2b), 1.55 (1H, m, H-11a), 1.61 (1H, m, H-24b), 1.65 (1H, m, H-8), 1.67 
(1H, m, H-24a), 1.69 (1H, m, H-17), 1.71 (1H, m, H-1a), 1.75 (2H, m, H-2a, H-12a), 1.98 (1H, 
m, H-15a), 2.05 (1H, m, H-25), 2.16 (1H, dt, J=12.4, 4.2 Hz, H-7a), 2.25 (1H, p, J=7.0 Hz, H-
20), 2.40 (1H, dd, J=10.4, 4.2 Hz, H-4a), 3.05 (1H, t, J=9.1 Hz, H-4'), 3.23 (1H, t, J=11.1 Hz, H-
5''b), 3.26 (1H, dd, J=9.2, 7.5 Hz, H-2''), 3.32 (1H, m, H-5'), 3.33 (1H, m, H-3''), 3.35 (1H, m, H-
2'), 3.36 (1H, t, J=11.6 Hz, H-26b), 3.40 (1H, m, H-6), 3.43 (1H, t, J=9.1 Hz, H-3'), 3.46 (2H, m, 
H-3, H-26a), 3.49 (1H, m, H-4''), 3.52 (1H, t, J=2.8 Hz, H-23), 3.90 (1H, dd, J=11.1, 5.4 Hz, H-
5''a), 4.32 (1H, d, J=7.8 Hz, H-1'), 4.45 (1H, td, J=7.7, 5.5 Hz, H-16), 4.48 (1H, d, J=7.5 Hz, H-
1''). 13C NMR (CD3OD, 126 MHz) į 13.8 (C-19), 16.7 (C-18), 17.0 (C-21), 17.4 (C-27), 18.2 (C-
6'), 22.0 (C-11), 25.0 (C-25), 31.9 (C-2), 32.7 (C-4), 33.0 (C-15), 35.3 (C-8), 37.6 (C-10, C-24), 
38.5 (C-1), 40.7 (C-12), 41.6 (C-7), 41.7 (C-20), 42.1 (C-13), 51.8 (C-5), 55.1 (C-9), 57.5 (C-
14), 65.7 (C-17), 67.1 (C-5''), 67.5 (C-26), 71.0 (C-4''), 71.1 (C-23), 71.8 (C-3), 72.7 (C-5'), 75.2 
(C-2'), 75.3 (C-4', C-2''), 77.7 (C-3''), 80.3 (C-6), 82.4 (C-16), 87.7 (C-3'), 104.8 (C-1'), 106.0 (C-
1''), 110.0 (C-22). ESI-HRMS m/z 727.4292 [M+H]+ (calculated for C38H63O13ǻSSP
= 3.2). 
Compound 6, Paniculonin A.1H NMR (CD3OD, 500 MHz) į 0.70 (1H, td, J=11.4, 3.7 Hz, H-9), 
0.86 (3H, s, Me-18), 0.88 (3H, s, Me-19), 0.96 (1H, m, H-7b), 0.96 (3H, d, J=7.0 Hz, Me-21), 
1.03 (1H, t, J=14.3 Hz, H-1b), 1.11 (3H, d, J=6.7 Hz, Me-27), 1.14 (1H, m, H-4b), 1.17 (2H, m, 
H-5, H-12b), 1.19 (1H, m, H-14), 1.27 (3H, d, J=6.1 Hz, Me-6'), 1.33 (1H, m, H-11b), 1.40 (1H, 
m, H-15b), 1.41 (1H, m, H-2b), 1.55 (1H, brd, J=13.7 Hz, H-11a), 1.68 (2H, m, H-8, H-24b), 
1.72 (1H, m, H-1a), 1.75 (1H, m, H-12a), 1.76 (2H, m, H-2a, H-17), 1.89 (1H, m, H-25), 1.90 
(1H, m, H-24a), 1.95 (1H, m, H-15a), 2.17 (1H, dt, J=12.6, 4.4 Hz, H-7a), 2.40 (1H, brd, J=11.3 
Hz, H-4a), 2.53 (1H, p, J=7.0 Hz, H-20), 3.05 (1H, t, J=9.0 Hz, H-4'), 3.19 (1H, d, J=11.4 Hz, H-
26b), 3.23 (1H, t, J=11.2 Hz, H-5''b), 3.26 (1H, dd, J=9.1, 7.6 Hz, H-2''), 3.31 (1H, m, H-5'), 3.32 
(1H, m, H-3''), 3.34 (1H, m, H-2'), 3.40 (1H, m, H-6), 3.43 (1H, t, J=9.0 Hz, H-3'), 3.46 (1H, m, 
H-3), 3.50 (1H, m, H-4''), 3.66 (1H, dd, J=10.3, 5.2 Hz, H-23), 3.85 (1H, d, J=11.0 Hz, H-26a), 
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3.90 (1H, dd, J=11.2, 5.4 Hz, H-5''a), 4.32 (1H, d, J=7.8 Hz, H-1'), 4.44 (1H, q, J=7.4 Hz, H-16), 
4.48 (1H, d, J=7.6 Hz, H-1''). 13C NMR (CD3OD, 126 MHz) į 13.3 (C-19), 13.8 (C-21), 16.5 (C-
18), 17.1 (C-27), 17.7 (C-6'), 21.6 (C-11), 30.9 (C-25), 31.4 (C-2), 32.0 (C-15), 32.1 (C-4), 34.5 
(C-8), 35.5 (C-24), 36.6 (C-20), 37.2 (C-10), 37.9 (C-1), 40.8 (C-12), 41.2 (C-7), 42.0 (C-13), 
51.2 (C-5), 54.6 (C-9), 56.9 (C-14), 62.6 (C-17), 63.5 (C-23), 64.7 (C-26), 66.5 (C-5''), 70.6 (C-
4''), 71.3 (C-3), 72.3 (C-5'), 74.6 (C-2'), 74.8 (C-2''), 74.9 (C-4'), 77.1 (C-3''), 79.7 (C-6), 82.1 (C-
16), 87.2 (C-3'), 104.3 (C-1'), 105.5 (C-1''), 112.0  (C-22). ESI-HRMS m/z 727.4302 [M+H]+ 
(calculated for C38H63O13, 727.4269, ǻppm = 4.5) 
 
Aglycone 7a/7b 
Solanolide 7a. 1H NMR (CD3OD, 500 MHz) G 0.73 (1H, m, H-9), 0.73 (3H, s, Me-18), 0.85 (3H, 
s, Me-19), 0.95 (1H, m, H-7b), 1.03 (2H, m, H-1b, H-5), 1.17 (2H, m, H-4b, H-12b), 1.21 (1H, 
m, H-14), 1.28 (3H, d, J=8.0 Hz, Me-21), 1.36 (1H, m, H-11b), 1.41 (1H, m, H-2b), 1.47 (1H, m, 
H-15b), 1.58 (1H, m, H-11a), 1.63 (1H, m, H-8), 1.72 (1H, m, H-1a), 1.76 (1H, m, H-2a), 1.81 
(1H, m, H-12a), 1.97 (1H, m, H-7a), 1.98 (1H, m, H-17), 2.18 (1H, m, H-4a), 2.30 (1H, m, H-
15a),  2.61 (1H, m, H-20), 3.34 (1H, m, H-6), 3.49 (1H, m, H-3), 5.03 (1H, td, J=7.8, 4.6 Hz, H-
16). 13C NMR (CD3OD, 126 MHz) į 13.6 (C-19), 13.9 (C-18), 17.9 (C-21), 21.4 (C-11), 31.6 
(C-2), 32.8 (C-4), 33.8 (C-15), 34.7 (C-8), 37.4 (C-20), 37.6 (C-10), 38.3 (C-1), 38.7 (C-12), 
42.2 (C-13), 42.3 (C-7), 52.6 (C-5), 54.9 (C-9), 55.4 (C-14), 59.9 (C-17), 69.6 (C-6), 71.7 (C-3), 
84.6 (C-16), 183.9 (C-22). ESI-HRMS m/z 363.2530 [M+H]+ (calculated for C22H3543, 363.2535, ȴppm = 
1.4). 
Solanolide-20-epimer 7b. 1H NMR (CD3OD, 500 MHz) G 0.73 (1H, m, H-9), 0.81 (3H, s, Me-
18), 0.85 (3H, s, Me-19), 0.95 (1H, m, H-7b), 1.03 (2H, m, H-1b, H-5), 1.17 (2H, m, H-4b, H-
12b), 1.21 (1H, m, H-14), 1.30 (3H, d, J=8.1 Hz, Me-21), 1.36 (1H, m, H-11b), 1.41 (1H, m, H-
2b), 1.47 (1H, m, H-15b), 1.58 (1H, m, H-11a), 1.63 (1H, m, H-8), 1.72 (1H, m, H-1a), 1.76 (1H, 
m, H-2a), 1.81 (1H, m, H-12a), 1.97 (1H, m, H-7a), 2.18 (1H, m, H-4a), 2.30 (1H, m, H-15a),  
2.31 (1H, m, H-17), 2.97 (1H, m, H-20), 3.34 (1H, m, H-6), 3.49 (1H, m, H-3), 4.83 (1H, td, 
J=7.3, 3.7 Hz, H-16). 13C NMR (CD3OD, 126 MHz) į 10.3 (C-21), 13.5 (C-19), 14.0 (C-18), 
21.4 (C-11), 31.6 (C-2), 32.8 (C-4), 33.8 (C-15), 34.7 (C-8), 37.6 (C-10), 38.3 (C-1), 38.7 (C-
20), 38.7 (C-12), 42.2 (C-13), 42.3 (C-7), 52.6 (C-5), 54.9 (C-9), 55.4 (C-14), 56.6 (C-17), 69.6 
(C-6), 71.7 (C-3), 84.1 (C-16), 182.2 (C-22). ESI-HRMS m/z 363.2522 [M+H]+ (calculated for C22H3543, 
363.2535, ȴppm = 3.6). 
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Animals 
Zebrafish. Adult zebrafish (AB strain) were reared at 28°C on a 14/10-hour light/dark cycle 
according to standard aquaculture conditions. Eggs were collected following natural spawning, 
VRUWHGDQGUDLVHGLQ['DQLHDX¶VVROXWLRQP0+(3(6S+P01D&O, 0.21 mM 
KCl, 0.12 mM MgSO4, and 0.18 mM Ca(NO3)2)  under constant light conditions in an incubator 
set at 28°C until 6 or 7 dpf. All zebrafish experiments carried out were approved by the Ethics 
Committee of the University of Leuven. 
Evaluation of anticonvulsant activity 
Automated larval zebrafish-PTZ assay. One 7-dpf zebrafish larva was placed per well in a 96-
well plate. Excess larval medium was removed and replaced with 100 µL of either control or 
sample solution. The prepared plate was placed in a dark box inside an incubator, set at 28°C, for 
1 or 18 hours, and subsequently inspected per well for signs of toxicity (e.g., irregular heart-rate, 
loss of posture, edema, necrosis, delayed startle or touch response). The maximum tolerated 
concentration (MTC) was designated as the highest sample concentration that did not elicit any 
signs of toxicity in 6/7-dpf larvae after 18 hours of exposure (Afrikanova, 2013).  Upon addition 
of 100 µL of 40 mM PTZ per well, the plate was positioned in the zebrafish tracking box 
(Viewpoint, Lyon, France), and the larvae allowed to habituate for 5 minutes before recording 
for 30 minutes, with movement values determined at 5 minute intervals. Tracking data was 
exported into Excel format and processed as such before statLVWLFDO DQDO\VLV YLD *UDSK3DG
Prism v.5 for Windows. Each tracking data set was normalized against the PTZ-only control 
values (set at 100%) within each set, with each subsequent replicate set pooled before two-way 
ANOVA with Bonferroni post hoc analysis. 
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Xenopus laevis GABAA receptor overexpression system 
Oocyte preparation and injection. The use of animals and all experimental procedures were 
approved by local authorities (Regierungspraesidium Tuebingen, Tuebingen, Germany). Oocytes 
were obtained from the Institute of Physiology I, Tübingen. Preparation of oocytes for recordings 
included treatment with collagenase (1mg/ml of type CLS II collagenase, Biochrom KG, Berlin, 
Germany) in OR2 solution (mM: 82.5 NaCl, 2.5 KCl, 1 MgCl2 and 5 HEPES, pH 7.6), followed 
by thorough washing and storing at 16 °C in Barth solution (mM:88 NaCl, 2.4 NaHCO3, 1 KCl, 
0.33 Ca(NO3)2, 0.41 CaCl2, 0.82 MgSO4 and 5 Tris/HCl, pH 7.4 with NaOH) supplemented with 
50 Lg/ml gentamicin (Biochrom KG, Germany). For injection and recording oocytes were plated 
in 96 well plates. All cRNA concentrations were adjusted to 800 ng/subunit and 70nl of the 
ĮȕȖVF51$PL[HG LQD UDWLRZHUH LQMHFWHG LQHDFKRRF\WHXVLQJ URERRLQMHFW0XOWL
Channel Systems, Reutlingen, Germany). Recordings were done at day 3 after injection. 
Amplitudes of interest for all currents recorded from the same oocyte were normalized to the 
first GABA pulse.  
Automated oocyte two-microelectrode voltage clamp. The currents in oocytes were recorded at 
room temperature (20-22°C) using roboocyte2® (Multi Channel Systems, Reutlingen, 
Germany).  Prepulled and prepositioned intracellular glass microelectrodes had a resistance of 
0.3±1 MO when filled with 1 M KCl/ 1.5 M KAc. The bath solution was ND96 (im mM: 93.5 
NaCl, 2 KCl, 1.8 CaCl2, 2 MgCl2 and 5 Hepes; pH 7.5). All compounds were applied for 15sec 
followed by 5 minutes washout with ND96. 
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Figure 1. (A-C) PTZ-induced activity curve for a 30-minute tracking period of 7-dpf zebrafish 
larvae after 18-hour pre-treatment with different concentrations of (A) S. torvum aqueous extract 
(from serial extractions of increasing polarity), (B) S. torvum methanol crude extract, (C) S. 
torvum decoction. (D) Total movement after 30-minute tracking period (expressed in %activity) 
of A-C, represented in a bar graph. All results were normalized against PTZ controls (set at 
100%). Analysis of the activity curves was done by two-way ANOVA, with P values < 0.05 (*), 
< 0.01 (**) and < 0.001 (***) indicated per 5-minute time slice. For the bar graph, statistical 
analysis was done by one-way ANOVA with DunnetW¶V7HVWWRDVVHVVthe samples vs. PTZ-only 
controls, with P values < 0.05 (*), < 0.01 (**) and < 0.001 (***). 
Figure 2. UHPLC-TOF-MS analysis of the methanolic and water extracts of S. torvum. 
Figure 3. A) HPLC-microfractionation of the methanolic extract of S. torvum. B) Active zone 
contain antiepileptic compounds. C) MS spectra of the main compounds present in the active 
zone. 
Figure 4. Isolated compounds from the methanolic extract of S. torvum, the common aglycone 
obtained by acid hydrolysis of the extract, and the structure of the ganaxolone. 
Figure 5. PTZ-induced activity curve for a 30-minute tracking period of 7-dpf zebrafish larvae 
after 18-hour pre-treatment with different concentrations of compounds 1-6 (number labels on 
each graph correspond to compound). Total movement after 30-minute tracking period 
(expressed in %activity) represented in a bar graph (7) below. All results were normalized 
against PTZ controls (set at 100%). Analysis of the activity curves was done by two-way 
ANOVA, with P values < 0.05 (*), < 0.01 (**) and < 0.001 (***) indicated per time period. For 
the bar graph, statistical analysis was done by one-ZD\$129$ZLWK'XQQHWW¶V7HVWWRDVVHVV
the samples vs. PTZ-only controls, with P values < 0.05 (*), < 0.01 (**) and < 0.001 (***). 
 
30 
 
Figure 6. PTZ-induced activity curve for a 30-minute tracking period of 7-dpf zebrafish larvae 
after 18-hour pre-treatment with different concentrations of (A) compound 7 (solanolide), and 
(B) 8 (ganaxolone). All results were normalized against PTZ controls (set at 100%). Analysis 
was done by two-way ANOVA, with P values < 0.05 (*), < 0.01 (**) and < 0.001 (***) 
indicated per time period. 
Figure 7. (A) Representative current traces generated in response to 1mM GABA or 10µM of 
indicated compounds applied for 15 seconds on Xenopus laevis oocytes expressing Į1ȕ2Ȗ2s 
receptors. (B) Responses to application of indicated compounds normalized to 1mM GABA 
applied at the beginning of each recording; n= 4-6. (C) Responses to compounds applied together 
with 10µM GABA in 10µM or 100µM concentrations and normalized to the response to 10µM 
GABA applied at the beginning of each recording. Washing time between applications was 5 
min; n=4  
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Figure 5 
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Figure 6 
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